89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
89bio, Inc. (ETNB) Tops Q2 EPS by 8c
August 5, 2024 5:38 PM EDT89bio, Inc. (NASDAQ: ETNB) reported Q2 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56).
For earnings history and earnings-related data on 89bio, Inc. (ETNB) click here.
... More89bio Inc. (ETNB) Appoints Charles McWherter to its Board
August 5, 2024 8:04 AM EDT89bio, Inc. (Nasdaq: ETNB) today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024.
We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors, said Rohan Palekar, CEO of 89bio. His expertise in drug development and profound knowledge of liver inflammation and fibrosis will be highly valuable as we advance our Phase 3 trials for non-cirrhotic and... More
